Piśmiennictwo
1. Zipes DP, Camm AJ, Borggrefe M, et al. American College of Cardiology, American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm association, Heart Rhythm Society: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8(9): 746-837.
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345(20): 1473-1482.
3. Adabag AS, Therneau TM, Gersh BJ. Sudden death after myocardial infarction. JAMA 2008; 300 (17): 2022-2029.
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877-83.
5. Bardy GH, Lee KL, Mark DB. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (3): 225-37.
6. Wijns W, Kolh P, Danchin N, et al. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 2532.
7. Dickstein K, Cohen-Solal A, Filippatos G, et al. The Task Force for the Diagnosis and Treatmnet of Acute and Chronic Heart Failure 2008 of The European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
8. Hohnloser SH, Conolly SJ, Kuck KH, et al. The Defibrillator in Acute Myocardial Infarction trial (DINAMIT): study protocol. Am Heart J 2000; 140(5): 735-9.
9. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic Use of Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction. N Engl J Med 2004; 351(24): 2481-8.
10. Steinbeck G, Andresen D, Senqes J, et al. Immediate Risk-Stratification Improves Survival (IRIS): study protocol. Europace 2004; 6(5): 329-9.
11. Goldenberg I, Vyas AK, Jackson W. Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. JACC 2008; 51(3): 288-96.
12. Chertow GM, Normand SLT, Silva LR, et al. Survival after acute myocardial infarction in patients with end-stage renal disease results from the Cooperative Cardiovascular Project. Am J Kidney Dis 2000; 35: 1044-51.
13. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
14. Anavekar NS, McMurray JJ, Velazquez E, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
15. Douglas SL, Krahn AD, Healey JS, et al. Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation insights from the Ontario ICD database. JACC 2010; 55(23): 774-82.
16. Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2011; 58 (10): 1007-13.
17. Haines JV, Wang Y, Curtis J, et al. Implantable cardioverter-defibrilltaor registry risk score models for acute procedural complication or death after implantable cardioverter-defibrillator implantation. Circulation 2011; 123(19): 2069-76.
18. Freeman JV, Wang Y, Curtis JP, et al. The relation between hospital procedure volume and complications of cardioverter-defibrillator implantation from the implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2010; 56(14): 1133-9.
19. Van Rees JB, De Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systemic review of randomized clinical trials. J Am Coll Cardiol 2011; 58(10): 995-1000.
20. Pedersen S, Hoogwegt MT, Jordaens L. Relation of Symptomatic Heart Failure and Psychological Status to Persistent Depression in Patients With Implantable Cardioverter-Defibrillator. Am J Cardiol 2011; 108(1): 69-74.
21. Suzuki T, Shiga T, Kuwahara K, et al. Prevalence and persistence of depression in patients with implantable cardioverter defibrillator: a 2 year longitudinal study. Pacin Clin Electrophysiol 2010; 33: 1455-61.
22. Jordan J, Sperzel J. Psychocardiological practice guidelines for ICD implantation and long-term care. Herzschrittmacherther Elektrophysiol 2011; 22(3): 140-5.
23. Lemon J, Edelman S. Psychological adaptation to ICDs and the influence of anxiety sensitivity. Psychol Health Med 2007; 12(2): 163-71.
24. Haas BK. A multidisciplinary concept analysis of quality of life. West J Nurs Res 1999; 21: 728-742.
25. Tokano T, Bach D, Chang J, et al. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol 1998; 9(8): 791-797.
26. Steinbeck G, Dorwarth U, Mattke S, et al. Hemodynamic deterioration during ICD implant: predictor of high-risk patients. Am Heart J 1994; 127(4) part 2: 1064-1067.
27. Birk AV, Leno E, Robertson HD, et al. Interaction between ATP and catecholamines in stimulation of platelet aggregation. Am J Physiol Heart Circ Physiol 2003; 284 (2):
H619-H625.
28. Voller H, Kamke W, Klein HU, et al. Clinical practice od defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II Registry. Europace 2011; 13: 499-508.
29. Średniawa B, Mazurek M, Lenarczyk R, et al. Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. Future Cardiol 2010; 6(3): 315-323.